Onco-Innovations Acquires Inka Health to Boost Cancer Research with AI

Onco-Innovations Limited, based in Vancouver, has announced the acquisition of Inka Health Corp, a software firm specializing in AI-driven analytics and multimodal data for clinical research and drug development. Onco issued 1,775,147 common shares for this transaction, subject to resale restrictions over time.

The acquisition aims to enhance Onco's cancer detection and drug development capabilities by integrating Inka Health's SynoGraph™ platform. This technology combines various datasets to provide insights into disease mechanisms, enabling more personalized treatment strategies. Inka's expertise is supported by partnerships with major industry players like AstraZeneca Canada.

This move is seen as a significant step for Onco in advancing AI-powered precision oncology, with both companies expressing optimism about future research and treatment advancements.